Ken Griffin Alector, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$4.34 - $6.58 $36,022 - $54,614	8,300 Added 98.81%	16,700 $77,000
Q2 2024 Aug 14, 2024	SELL	$4.19 - $6.23 $10,475 - $15,575	-2,500 Reduced 22.94%	8,400 $38,000
Q1 2024 May 15, 2024	SELL	$5.69 - $8.08 $113,800 - $161,600	-20,000 Reduced 64.72%	10,900 $65,000
Q4 2023 Feb 14, 2024	BUY	$3.77 - $8.39 $29,783 - $66,281	7,900 Added 34.35%	30,900 $246,000
Q3 2023 Nov 14, 2023	SELL	$5.2 - $8.77 $35,360 - $59,636	-6,800 Reduced 22.82%	23,000 $149,000
Q2 2023 Aug 14, 2023	SELL	$5.86 - $7.93 $30,472 - $41,236	-5,200 Reduced 14.86%	29,800 $179,000
Q1 2023 May 15, 2023	SELL	$5.85 - $9.84 $1.04 Million - $1.75 Million	-177,700 Reduced 83.54%	35,000 $216,000
Q4 2022 Feb 14, 2023	SELL	$6.88 - $9.55 $9,632 - $13,370	-1,400 Reduced 0.65%	212,700 $1.96 Million
Q3 2022 Nov 14, 2022	SELL	$8.19 - $13.2 $72,891 - $117,480	-8,900 Reduced 3.99%	214,100 $2.03 Million

167

57.8M

146K

90.8K

Ticker ALEC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,563,904
Market Cap $310M
Description
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.